DETERMINE: Detemir vs NPH
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 336 participants.
Also called NCT05124457
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 336 participants
- Registry
-
NCT05124457
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT05124457. Randomized; no masking; primary purpose treatment. Start 2022-02-01 (actual); primary completion 2025-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- DETERMINE: Detemir vs NPH
- Acronym
- DETERMINE
- Condition
- Gestational Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin Detemir
- Intervention (Drug)
- Insulin NPH
- Lead sponsor
- University of California, Los Angeles
Record details
- Record id
cardio:ct-nct05124457- Content hash
47075d4f46388e9bb9532c71e3fa6517691c5a040aa6a42936205b424facd40d